Medication info
Kairoutin Tablet 10mg (Rosuvastatin Calcium)

Kairoutin Tablet 10mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Korea Chorus Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets (15 tablets/PTP*2), 30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201701549 · Approved 2017.03.31

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more, according to LDL cholesterol levels, treatment goals, and patient response; it may be increased up to a maximum of 20 mg daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of this medicine at a dose of 40 mg is contraindicated in some of these patients.
Children's dosage
Ages 10 to 17 years: The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on doses greater than 20 mg in pediatric patients.) The dose should be individualized according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or more. Under 10 years: Safety and efficacy have not been established.

Ingredients

Manufacturer
Korea Chorus Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is used as an adjunct when dietary changes or exercise alone are insufficient to control dyslipidemia, such as primary hypercholesterolemia and mixed dyslipidemia. It is also helpful in patients with homozygous familial hypercholesterolemia when used alongside dietary therapy or other lipid-lowering therapies. In patients with hypercholesterolemia, it lowers total cholesterol and LDL-cholesterol levels, thereby slowing the progression of atherosclerosis. It is particularly useful for some pediatric patients aged 10 to 17 years and helps reduce cholesterol levels in patients with heterozygous familial hypercholesterolemia. This drug is also used as an adjunct to dietary therapy in patients with primary dysbetalipoproteinemia and contributes to reducing the risk of stroke and myocardial infarction in high-risk groups by decreasing the risk of arterial revascularization and cardiovascular disease. In summary, this drug is effectively used in various types of hypercholesterolemia and to reduce the risk of cardiovascular disease.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more, according to LDL cholesterol levels, treatment goals, and patient response; it may be increased up to a maximum of 20 mg daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of this medicine at a dose of 40 mg is contraindicated in some of these patients.

Children's dosage

Ages 10 to 17 years: The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on doses greater than 20 mg in pediatric patients.) The dose should be individualized according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or more. Under 10 years: Safety and efficacy have not been established.

Precautions

This drug should not be used in certain patients. For example, patients who are allergic to any of the components, those with severe liver dysfunction, muscle diseases, or severe kidney dysfunction should not take this medication. Women who are pregnant or breastfeeding, and women of childbearing potential not using appropriate contraception should also not take this medication, and women of childbearing age should be fully informed of the potential risks to pregnancy and the fetus. This drug requires special caution in patients at high risk of muscle damage, such as those with moderately or severely impaired renal function, hypothyroidism, those with a family history of muscle disease or past muscle toxic reactions, alcoholics, and those taking specific drugs concurrently. Moreover, since this drug contains lactose, patients with lactose intolerance or related genetic disorders should not take it. Before and during treatment with this drug, liver function tests should be conducted regularly to check liver status. Patients with a history of liver disease or excessive alcohol consumption require extra caution. If symptoms such as myalgia, muscle weakness, or cramps occur, inform a physician immediately, and in severe cases, discontinue the medication. Additionally, it is advisable to avoid tests for muscle damage after vigorous exercise. This drug may interact with other medications; therefore, if other medications are being taken, patients must inform their doctor or pharmacist and consult them. Particular care should be taken when combined with certain antiviral agents, immunosuppressants, antibiotics, or fibrates, as the risk of muscle damage may increase. Pregnant or breastfeeding women, or women planning to become pregnant should not take this medication, and if pregnancy is confirmed during treatment, it should be discontinued immediately. In case of overdose, as there is no specific antidote, treatment should be symptomatic while monitoring liver function and markers of muscle damage. This drug does not significantly impact the ability to drive or operate machinery; however, patients should be cautious as dizziness may occur. If severe skin reactions or allergic symptoms occur while taking this drug, it should be stopped immediately, and medical advice should be sought.

Side effects

Angioedema, allergic reaction, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia and systemic symptoms drug reaction syndrome, drug-induced lichenoid rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, joint pain, fatigue, numbness, paresthesia, chest discomfort, appetite loss, abdominal distension, abnormal liver function tests, syncope, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly closed container. It is essential to maintain the storage temperature between 1 and 30 degrees Celsius to preserve the medication's effectiveness.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets (15 tablets/PTP*2), 30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.